Nutriband (NTRB) Price & Analysis

Compare

137 Followers

NTRB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.72 - $11.78

Previous CloseN/A

Volume13.23K

Average Volume (3M)139.07K

Market Cap

$71.16M

Enterprise Value$59.94M

Total Cash (Recent Filing)$2.96M

Total Debt (Recent Filing)$282.44K

Price to Earnings (P/E)―

Beta1.49

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.98

Shares Outstanding11,154,171

10 Day Avg. Volume28,817

30 Day Avg. Volume139,075

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.84

Enterprise Value/Revenue24.99

Enterprise Value/Gross Profit76.00

Enterprise Value/Ebitda-6.19

Forecast

1Y Price Target

$15.00

Price Target Upside139.62% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Market ExpansionThe safety features of the AVERSA Fentanyl patch could lead to decreased restrictions and increased access for patients with severe chronic pain, potentially expanding the market.

Partnership DevelopmentsNutriband's partnership with Kindeva Drug Delivery enhances the potential of the AVERSA technology by incorporating it into Kindeva’s transdermal fentanyl patch.

Technology InnovationNutriband's proprietary AVERSA technology offers abuse-deterrent features that differentiate it from other transdermal patches on the market.

Bears Say

Development CostsThe amended agreement between Nutriband and Kindeva involves cost sharing, which could impact financial resources during the development phase.

Nutriband News

Nutriband CEO Gareth Sheridan steps aside for Irish election

Nutriband (NTRB) has announced that company CEO, Gareth Sheridan will be stepping aside from his role for three...

29d ago

NTRB

Nutriband Issues Shares Amid Investor Engagement

Nutriband ( ($NTRB) ) has issued an announcement. Between February 1 and July 31, 2025, Nutriband saw the...

6d ago

NTRB

Nutriband announces FDA granted Type C Meeting for AVERSA FENTANYL

Nutriband (NTRB) announced that the United States Food and Drug Administration, FDA, has granted a Type C Meeting...

1M ago

NTRB

Nutriband Completes Stock Dividend of Preferred Shares

An update from Nutriband ( ($NTRB) ) is now available. On July 9, 2025, Nutriband‘s Board of Directors...

1M ago

NTRB

Nutriband confirms record, pay date for 25% preferred stock dividend

Nutriband (NTRB) is reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend. Shareholders...

2M ago

NTRB

Nutriband Approves New Series A Preferred Stock

An update from Nutriband ( ($NTRB) ) is now available. On July 9, 2025, Nutriband Inc.’s Board of...

2M ago

NTRB

Nutriband board approves 25% Preferred Stock dividend

Nutriband’s (NTRB) Board of Directors has approved and declared a 25% preferred stock dividend. Shareholders of record on...

2M ago

NTRB

Nutriband added to Russell Microcap, Russell Microcap Growth, Russell 3000E

Nutriband (NTRB) has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and...

2M ago

NTRB

Nutriband, Kindeva complete commercial manufacturing process scale-up for Aversa

Nutriband (NTRB) has completed commercial manufacturing process scale-up for its lead product, Aversa Fentanyl, with Kindeva. Nutriband is...

3M ago

NTRB

Nutriband issued U.S. patent for transdermal abuse deterrent technology

Nutriband (NTRB) announced that the United States Patent and Trademark Office issued patent number 12,318,492 on June 3,...

3M ago

NTRB

Nutriband reports Q1 revenue up 63% y/y at $667K

The company states: “Nutriband (NTRB) is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary,...

3M ago

NTRB

Nutriband Inc trading halted, volatility trading pause

09:34 EDT Nutriband (NTRB) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source...

4M ago

NTRB

Nutriband Inc trading resumes

09:39 EDT Nutriband (NTRB) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

4M ago

NTRB

Nutriband Partners with Charlotte FC for Brand Visibility

Nutriband ( ($NTRB) ) has issued an announcement. On April 4, 2025, Nutriband Inc. announced an Associate Partnership...

5M ago

NTRB

NTRB FAQ

What was Nutriband Inc’s price range in the past 12 months?

Nutriband Inc lowest stock price was $3.72 and its highest was $11.78 in the past 12 months.

What is Nutriband Inc’s market cap?

Nutriband Inc’s market cap is $71.16M.

When is Nutriband Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nutriband Inc’s earnings last quarter?

Nutriband Inc released its earnings results on May 28, 2024. The company reported -$0.207 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.207.

Is Nutriband Inc overvalued?

According to Wall Street analysts Nutriband Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nutriband Inc pay dividends?

Nutriband Inc does not currently pay dividends.

What is Nutriband Inc’s EPS estimate?

Nutriband Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nutriband Inc have?

Nutriband Inc has 11,154,171 shares outstanding.

What happened to Nutriband Inc’s price movement after its last earnings report?

Nutriband Inc reported an EPS of -$0.207 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.

Which hedge fund is a major shareholder of Nutriband Inc?

Currently, no hedge funds are holding shares in NTRB

Nutriband Stock Smart Score

Outperform

Fundamentals

Return on Equity

-108.02%

Trailing 12-Months

Asset Growth

-59.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nutriband Inc

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Nutriband (NTRB) Earnings & Revenues

Historic Earnings Reports

NTRB Stock 12 Month Forecast

Average Price Target

$15.00

▲(139.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","5.5":"$5.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2022","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.39,7.975384615384615,8.56076923076923,9.146153846153846,9.731538461538461,10.316923076923077,10.902307692307692,11.487692307692306,12.073076923076922,12.658461538461538,13.243846153846153,13.829230769230769,14.414615384615384,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.39,7.975384615384615,8.56076923076923,9.146153846153846,9.731538461538461,10.316923076923077,10.902307692307692,11.487692307692306,12.073076923076922,12.658461538461538,13.243846153846153,13.829230769230769,14.414615384615384,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.39,7.975384615384615,8.56076923076923,9.146153846153846,9.731538461538461,10.316923076923077,10.902307692307692,11.487692307692306,12.073076923076922,12.658461538461538,13.243846153846153,13.829230769230769,14.414615384615384,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.54,"date":1651363200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.61,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.5,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.5,"date":1656633600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.55,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.39,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >